Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
NCT00224406
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
114
Enrollment
INDUSTRY
Sponsor class
Conditions
Ischemia-Reperfusion Injury
Lung Transplantation
Interventions
DRUG:
Repertaxin
OTHER:
Placebo
Sponsor
Dompé Farmaceutici S.p.A